<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Irinotecan and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (5-FU) are used to treat <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Irinotecan's active metabolite is inactivated by <z:chebi fb="15" ids="17659">UDP</z:chebi>-glucuronosyltransferase 1A1 (UGT1A1), which is deficient in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Irinotecan and metabolites are transported by P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, encoded by ABCB1 </plain></SENT>
<SENT sid="3" pm="."><plain>5-FU targets <z:chebi fb="3" ids="37445">folate</z:chebi> metabolism through inhibition of thymidylate synthase (TYMS) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="25297">Methylenetetrahydrofolate</z:chebi> reductase (MTHFR) generates active <z:chebi fb="3" ids="37445">folate</z:chebi> necessary for haematopoiesis </plain></SENT>
<SENT sid="5" pm="."><plain>We retrospectively genotyped 140 Swedish and Norwegian irinotecan and 5-FU-treated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients from the Nordic VI clinical trial for selected variants of UGT1A1, ABCB1, TYMS and MTHFR </plain></SENT>
<SENT sid="6" pm="."><plain>We found an increased risk of clinically relevant early toxicity in patients carrying the ABCB1 3435 T/T genotype, Odds ratio (OR)=3.79 (95% confidence interval (CI)=1.09-13.2), and in patients carrying the UGT1A1(*)28/(*)28 genotype, OR=4.43 (95% CI=1.30-15.2) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with UGT1A1(*)28/(*)28 had an especially high risk of <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, OR=6.87 (95% CI=1.70-27.7) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who had reacted with toxicity during the first two cycles were in total treated with fewer cycles (P&lt;0.001), and less often responded to treatment (P&lt;0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Genetic variation in ABCB1 was associated with both early toxicity and lower response to treatment </plain></SENT>
<SENT sid="10" pm="."><plain>Carriers of the ABCB1 1236T-2677T-3435T haplotype responded to treatment less frequently (43 vs 67%, P=0.027), and survived shorter time, OR=1.56 (95% CI=1.01-2.45) </plain></SENT>
</text></document>